Advanced search

Online first
Guidelines / Expert consensus
Published online: 2025-03-11

open access

View PDF Download PDF file
Page views 3
Article views/downloads 1
Get Citation

Connect on Social Media

Connect on Social Media

Experts’ position on durvalumab treatment for cholangiocarcinoma patients

Michał F. Kamiński123, Nastazja Pilonis1234, Leszek Kraj5, Maciej Kawecki6, Tomasz Kubiatowski7

Abstract

In the Polish population, biliary tract cancers account for about 1% of the incidence and 2.5% of deaths due to all cancers, with 85% of all cases diagnosed in patients over the age of 60. Biliary tract cancer is a neoplasm that originates from intrahepatic or extrahepatic biliary epithelial cells and shows features of cholangiocyte differentiation. It can also develop from perihilar glands and hepatocytes. It is characterized by a poor prognosis, while the use of exclusive chemotherapy in the treatment leads to a slight improvement in the treatment effect. The paper presents current guidelines for imaging and endoscopic diagnosis in patients with biliary tract cancer and summarizes data on the efficacy and safety of durvalumab from clinical trials as well as everyday clinical practice. 

Keywords: cholangiocrcinomaimmunotherapydurvalumab

Article available in PDF format

View PDF Download PDF file

References

  1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014; 383(9935): 2168–2179.
    CrossRefPubMed
  2. Zhu Y, Kwong LN. Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models. Hepatology. 2020; 72(1): 305–314.
    CrossRefPubMed
  3. Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1: 7–18.
    CrossRefPubMed
  4. Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1(Suppl 1): 63–78.
    CrossRefPubMed
  5. Blechacz B, Komuta M, Roskams T, et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8(9): 512–522.
    CrossRefPubMed
  6. Ilyas SI, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018; 15(2): 95–111.
    CrossRefPubMed
  7. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019; 39 Suppl 1: 19–31.
    CrossRefPubMed
  8. Paul A, Kaiser GM, Molmenti EP, et al. Klatskin tumors and the accuracy of the Bismuth-Corlette classification. Am Surg. 2011; 77(12): 1695–1699.
    PubMed
  9. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224(4): 463–73; discussion 473.
    CrossRefPubMed
  10. Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022; 76(5): 1109–1121.
    CrossRefPubMed
  11. Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021; 7(1): 65.
    CrossRefPubMed
  12. Didkowska J, Wojciechowska U, Michalek IM, et al. Cancer incidence and mortality in Poland in 2019. Sci Rep. 2022; 12(1): 10875.
    CrossRefPubMed
  13. Didkowska J, Barańska K, Miklewska M, et al. Rak dróg żółciowych w Polsce – obraz epidemiologiczny wraz z analizą postępowania terapeutycznego w latach 2016-2020. 2023.
  14. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9): 557–588.
    CrossRefPubMed
  15. Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. Eur J Surg Oncol. 2021; 47(3 Pt A): 503–513.
    CrossRefPubMed
  16. Khan S, Thomas H, Davidson B, et al. Cholangiocarcinoma. The Lancet. 2005; 366(9493): 1303–1314.
    CrossRef
  17. Rushbrook SM, Kendall TJ, Zen Y, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023; 73(1): 16–46.
    CrossRefPubMed
  18. Saluja SS, Sharma R, Pal S, et al. Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study. HPB (Oxford). 2007; 9(5): 373–382.
    CrossRefPubMed
  19. Trikudanathan G, Navaneethan U, Njei B, et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc. 2014; 79(5): 783–789.
    CrossRefPubMed
  20. Ni Q, Wang H, Zhang Y, et al. MDCT assessment of resectability in hilar cholangiocarcinoma. Abdom Radiol (NY). 2017; 42(3): 851–860.
    CrossRefPubMed
  21. Joo I, Lee JM. Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection. Abdom Imaging. 2013; 38(6): 1334–1350.
    CrossRefPubMed
  22. Lamarca A, Barriuso J, Chander A, et al. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol. 2019; 71(1): 115–129.
    CrossRefPubMed
  23. Ruys AT, van Beem BE, Engelbrecht MRW, et al. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol. 2012; 85(1017): 1255–1262.
    CrossRefPubMed
  24. Huang X, Yang J, Li J, et al. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2020; 99(35): e20932.
    CrossRefPubMed
  25. Shimada K, Isoda H, Hirokawa Y, et al. Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol. 2010; 20(11): 2690–2698.
    CrossRefPubMed
  26. Koc Z, Erbay G. Optimal b value in diffusion-weighted imaging for differentiation of abdominal lesions. J Magn Reson Imaging. 2014; 40(3): 559–566.
    CrossRefPubMed
  27. Franken LC, Coelen RJS, Erdmann JI, et al. Multidetector computed tomography assessment of vascular involvement in perihilar cholangiocarcinoma. Quant Imaging Med Surg. 2021; 11(11): 4514–4521.
    CrossRefPubMed
  28. Francica G, Meloni MF, de Sio I, et al. Biopsy of Liver Target Lesions under Contrast-Enhanced Ultrasound Guidance - A Multi-Center Study. Ultraschall Med. 2018; 39(4): 448–453.
    CrossRefPubMed
  29. Novikov A, Kowalski TE, Loren DE. Practical Management of Indeterminate Biliary Strictures. Gastrointest Endosc Clin N Am. 2019; 29(2): 205–214.
    CrossRefPubMed
  30. Yoon SB, Moon SH, Ko SW, et al. Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis. Dig Dis Sci. 2022; 67(7): 3284–3297.
    CrossRefPubMed
  31. Zhai J. UroVysion Multi-Target Fluorescence in situ Hybridization Assay for the Detection of Malignant Bile Duct Brushing Specimens: A Comparison with Routine Cytology. Acta Cytol. 2018; 62(4): 295–301.
    CrossRefPubMed
  32. Naitoh I, Nakazawa T, Kato A, et al. Predictive factors for positive diagnosis of malignant biliary strictures by transpapillary brush cytology and forceps biopsy. J Dig Dis. 2016; 17(1): 44–51.
    CrossRefPubMed
  33. Sun Xi, Zhou Z, Tian J, et al. Is single-operator peroral cholangioscopy a useful tool for the diagnosis of indeterminate biliary lesion? A systematic review and meta-analysis. Gastrointest Endosc. 2015; 82(1): 79–87.
    CrossRefPubMed
  34. Navaneethan U, Hasan MK, Lourdusamy V, et al. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc. 2015; 82(4): 608–14.e2.
    CrossRefPubMed
  35. Arechederra M, Rullán M, Amat I, et al. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut. 2022; 71(6): 1141–1151.
    CrossRefPubMed
  36. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000; 95(1): 204–207.
    CrossRefPubMed
  37. Valle JW, Borbath I, Khan SA, et al. ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5): v28–v37.
    CrossRefPubMed
  38. Lamarca A, Palmer DH, Wasan HS, et al. Advanced Biliary Cancer Working Group, ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14): 1273–1281.
    CrossRefPubMed
  39. Sharma A, Kalyan Mohanti B, Pal Chaudhary S, et al. Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial. Eur J Cancer. 2019; 123: 162–170.
    CrossRefPubMed
  40. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022; 1(8): EVIDoa2200015.
    CrossRefPubMed
  41. AstraZeneca AB. IMFINZI (durvalumab): EU summary of prod- uct characteristics. 2024. https://www.ema.europa.eu/.
  42. Oh DY, He A, Bouattour M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024; 9(8): 694–704.
    CrossRef
  43. Burris HA, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024; 25(5): 626–635.
    CrossRefPubMed
  44. Di Maio M, Perrone F, Conte P. Real-World Evidence in Oncology: Opportunities and Limitations. Oncologist. 2020; 25(5): e746–e752.
    CrossRefPubMed
  45. Seung SJ, Saherawala H, Syed I, et al. Real-world treatment patterns and survival outcomes for treated biliary tract cancer patients using administrative databases in Ontario. J Gastrointest Oncol. 2023; 14(4): 1806–1816.
    CrossRefPubMed
  46. Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data. Liver International. 2023; 43(8): 1803–1812.
    CrossRef
  47. Rimini M, Masi G, Lonardi S, et al. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. Target Oncol. 2024; 19(3): 359–370.
    CrossRefPubMed
  48. Rimini M, Fornaro L, Rizzato MD, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population. Eur J Cancer. 2024; 208: 114199.
    CrossRefPubMed
  49. Obwieszczenie Ministra Zdrowia z dnia 18 września 2024 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 października 2024 r. Program Lekowy B.5. https://www.gov.pl/web/zdrowie/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych.

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note